ClinicalTrials.gg
Not yet recruitingNCT07565857SIGNAL GEC-101Updated May 4, 2026

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

An interventional study of Signatera Genome ultra-sensitive ctDNA blood test in Gastric-Esophageal Cancer, sponsored by Natera, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Natera, Inc. · Not applicable, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer. The main question it aims to answer is:

  • To demonstrate if 2-year disease-free survival (DFS) among participants with resectable clinical Stage II-IVa gastric/gastro-esophageal cancer who received neoadjuvant D-FLOT and are ctDNA negative after curative intent R0 surgery receiving adjuvant durvalumab monotherapy is non-inferior to standard of care D-FLOT.

Researchers will compare post-operative ctDNA negative participants who are receiving adjuvant durvalumab monotherapy to those who receive standard of care (D-FLOT) to see if they have similar outcomes.

Participants will be asked to:

  • Receive serial ctDNA testing
  • Visit their study doctor per their standard of care visits about every 3 months for first 2 years and then every 6 months for an additional 3 years
  • Answer 5 questionnaires about their well-being
Read the detailed description

This is a prospective, open-label, multi-center, ctDNA-guided study with a randomized, non-inferiority component designed to examine clinical outcomes in treatment of gastric/gastric-esophageal cancer. Specifically, a component of the study will evaluate an adjuvant treatment de-escalation strategy for participants with resectable clinical Stage II-IVa gastric/gastric-esophageal cancer who have completed neoadjuvant therapy with durvalumab plus fluorouracil, leucovorin, oxaliplatin, docetaxel (D-FLOT) and R0 curative intent surgery. Concurrently, participants with post-operative ctDNA positive results will receive standard of care (SOC) D-FLOT with blinded serial ctDNA testing.

Following R0 curative intent surgery, participants will be consented for study participation. Eligible participants will undergo treatment assignment based on post-operative MRD status at 5 weeks (+/- 2 weeks), as determined by the Signatera assay.

Participants with negative post-operative circulating tumor DNA (ctDNA) results and no radiographic evidence of disease (within 6 weeks prior to randomization) will be randomized (1:1) to either SOC vs ct-DNA guided treatment. Randomized participants will be stratified according to pathologic (yp) lymph node status and tumor staging (ypT1-3, N0 vs T4 or N+), Combined Positive Score (CPS, CPS ≥ 1 vs CPS \<1), and pathological complete response (yes vs no). Assigned adjuvant treatment must start no later than 12 weeks post surgery.

  • Arm A (SOC Arm): Durvalumab for 1 year plus four 2 week cycles of FLOT with unblinded serial ctDNA testing and patient-reported outcomes (PROs) assessments.
  • Arm B (ctDNA-guided Arm): Durvalumab monotherapy for 1 year with unblinded serial ctDNA testing and PROs assessments. Participants who become ctDNA positive up through Cycle 11 Day 1 (C11D1) will receive four 2 week cycles of FLOT added to Durvalumab.

Once adjuvant therapy is completed, all randomized participants will continue with serial ctDNA testing until recurrence and followed for up to 5 years for overall survival (OS), disease-free survival (DFS), metastasis-free survival (MFS) and disease-specific survival (DSS).

Participants with post-operative ctDNA positive results at 5 weeks (+/- 2 weeks) will not be randomized. They will continue on observation and receive SOC D-FLOT with blinded serial ctDNA testing.

02

Conditions studied

  • Gastric-Esophageal Cancer

Keywords

  • ctDNA
  • Circulating tumor DNA
  • Gastric-Esophageal Cancer
  • Signatera
  • Molecular residual disease
  • MRD
  • Biomarker-guided therapy
  • Durvalumab
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Docetaxel
  • D-FLOT
  • Adjuvant therapy
  • Tumor-informed assay
  • Gastric Cancer
  • Esophageal Cancer
  • Gastric adenocarcinoma
  • ctDNA-guided
03

In context

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Natera, Inc. is the lead sponsor of 36 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated form (ICF) obtained prior to any trial-specific enrollment procedure.
  2. Age is ≥ 18 years-old at the time of ICF signature.
  3. Able to submit adequate (eg, 6 to 10 unstained slides at 10 microns (μm) each or 12-19 unstained slides at 5-microns (μm) plus one hematoxylin and eosin slide (see study lab manual) obtained per standard of care procedures for submission to a central laboratory for Signatera testing OR prior commercial Signatera Genome test results.
  4. confirmed adenocarcinoma of the stomach, esophagus and/or gastroesophageal junction (GEJ), resectable clinical Stage II-IVa per AJCC 9th edition.
  5. Completion of full or modified course (based on Dosing and Modification Guidelines) of D-FLOT therapy (ie, two 4-week cycles of durvalumab, four 2-week cycles of FLOT) .
  6. Has undergone complete surgical resection of the gastric/GEJ tumor with pathologically confirmed negative margins (R0 resection).
  7. Eligible to receive adjuvant D-FLOT treatment within 12 weeks postoperative per standard of care (SOC) as assessed by the treating clinician.
  8. Known statuses pertaining to randomization stratification factors:

    1. Post neoadjuvant, post-operative (yp) lymph node status and tumor staging (ypT1-3, N0 vs T4 or N+)
    2. Combined Positive Score ( ≥ 1 vs \<1)Tumor status confirmed by immunohistochemistry/CPS score.
    3. Post neoadjuvant, post-operative major pathological response (MPR): Yes/No
  9. performance status 0-1.
  10. No evidence of disease by radiographic imaging.
  11. Must be willing to and able to comply with adjuvant treatment plans based on ctDNA results and other trial-mandated procedures.
  12. Women of child bearing potential must have a confirmed negative pregnancy test within 14 days of enrollment per institutional standards.

Exclusion criteria

Exclusion Criteria:

  1. Histologic presence of adenosquamous cell carcinoma, squamous cell carcinoma, gastrointestinal stromal tumor, or neuroendocrine tumors.
  2. Radiographic evidence of unresectable disease (ie, IVb).
  3. Presence of peritoneal dissemination.
  4. Any prior therapy (eg, radiation, chemoradiation, chemotherapy) for gastric or gastroesophageal cancer other than D-FLOT and R0 curative intent surgery.
  5. Known contradiction or to durvalumab per the prescribing information; known or hypersensitivity to Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel or any of the drug .
  6. Known history of active primary immunodeficiency (eg, ), other contraindications of immunotherapy or receiving medication per approved label.
  7. Female participants who are pregnant or breastfeeding.
  8. Concurrent enrollment in another clinical trial unless the study is observational, non-interventional.
  9. Use of any commercial ctDNA or liquid monitoring outside of the study protocol during the primary 36-month monitoring period.
  10. Concurrent invasive or a prior invasive malignancy whose treatment was completed within 5 years before ICF signature. Note: Participants with prior or concurrent in situ malignancies are eligible provided that adequate curative treatment is completed prior to enrollment.
  11. Any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate participant participation in the clinical trial or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver disease, active untreated or uncontrolled fungal, bacterial or viral infections, active infection requiring systemic antibacterial therapy, etc.)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    ctDNA Guided (Durvalumab monotherapy for 1 year)

    Participants who become ctDNA positive up through C11D1 will receive four 2 week cycles of FLOT added to Durvalumab along with serial ctDNA testing.

    Device: Signatera Genome ultra-sensitive ctDNA blood test

  • Active comparator
    SOC (Durvalumab for 1 year plus four 2 week cycles of FLOT starting C1D1)

    Participants will receive Durvalumab for 1 year plus four 2 week cycles of FLOT starting C1D1 along with serial ctDNA testing.

    Device: Signatera Genome ultra-sensitive ctDNA blood test

Interventions

  • DeviceSignatera Genome ultra-sensitive ctDNA blood test

    Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with resectable clinical Stage II-IVa gastric/gastro-esophageal cancer who are ctDNA negative after R0 curative intent surgery. The test is used to identify patients with no evidence of MRD following definitive surgery.

This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS)

    The primary objective of this study is to evaluate if disease free survival (DFS) among patients with resectable clinical stage II-IVa gastric/gastro-esophageal cancer who are ctDNA-negative after surgery undergoing ctDNA-guided observation is non-inferior to adjuvant D-FLOT.

    Time frame: 2 years from randomization to the first occurrence of disease recurrence or death from any cause, whichever occurs first

Secondary outcomes

  1. Overall Survival (OS)

    Comparison of overall survival (OS) among Arm A (SOC) and Arm B (ctDNA guided) patients and assess whether adjuvant durvalumab monotherapy is non-inferior to standard of care adjuvant D-FLOT

    Time frame: From randomization to Year 3 and randomization to Year 5

  2. Molecular Recurrence

    Compare Arm A(SOC) relative to Arm B (ctDNA guided) time from surgery (or first ctDNA negative assessment) to the detection of ctDNA positivity by the Signatera assay.

    Time frame: From time of surgery up to 3 years

  3. Metastasis-Free Survival (MFS)

    To compare Arm A (SOC) relative to Arm B (ctDNA guided) on metastasis-free survival (MFS).

    Time frame: From randomization at Year 2, Year 3, and Year 5

  4. Disease-Specific Survival (DFS)

    To compare Arm A (SOC) relative to Arm B (ctDNA guided) on disease-specific survival (DFS).

    Time frame: From randomization at Year 2, Year 3, and Year 5

  5. Discontinuation due to Adverse Events

    Comparison of Arm A (SOC) relative to Arm B (ctDNA guided) on treatment discontinuation due to adverse events.

    Time frame: From enrollment to Year 2

  6. Quality of Life Outcomes

    Comparison of Arm A (SOC) relative to Arm B (ctDNA guided) on quality of life and disease-related symptoms using patient-reported outcomes (PROs) from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30).

    Time frame: From enrollment to Year 2

  7. Quality of Life Outcomes

    Comparison of Arm A (SOC) relative to Arm B (ctDNA guided) on quality of life and disease-related symptoms using patient-reported outcomes (PROs) from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Stomach Cancer Module (EORTC QLQ-STO22)

    Time frame: From enrollment to Year 2

  8. Quality of Life Outcomes

    Comparison of Arm A (SOC) relative to Arm B (ctDNA guided) on quality of life and disease-related symptoms using patient-reported outcomes (PROs) from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire ( EORTC-IL38).

    Time frame: From enrollment to Year 2

  9. Patient Reported Treatment Tolerability

    To compare Arm A (SOC) relative to Arm B (ctDNA guided) to the patient-reported tolerability of treatment using Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

    Time frame: From enrollment to Year 2

Other outcomes

  1. Assess ctDNA Clearance Arm B (ctDNA Guided)

    Assess ctDNA clearance patterns in participants who receive adjuvant FLOT only after molecular recurrence in Arm B (ctDNA guided).

    Time frame: From randomization to 2 years, 3 years, and 5 years

  2. Assess ctDNA Clearance in Arm A (SOC)

    Assess ctDNA clearance during and after adjuvant D-FLOT therapy in ctDNA positive cohort of Arm A (SOC).

    Time frame: From randomization to 2 years, 3 years, and 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. doi: 10.1200/JCO.2010.33.0597. Epub 2011 Mar 28. PubMed 21444866 ↗
  • Yang F, Hu Y, Shi Z, Liu M, Hu K, Ye G, Pang Q, Hou R, Tang K, Zhu Y. The occurrence and development mechanisms of esophageal stricture: state of the art review. J Transl Med. 2024 Jan 31;22(1):123. doi: 10.1186/s12967-024-04932-2. PubMed 38297325 ↗
  • Xu F, Feng G, Zhao H, Liu F, Xu L, Wang Q, An G. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Oct;94(43):e1911. doi: 10.1097/MD.0000000000001911. PubMed 26512615 ↗
  • Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One. 2015 Jun 26;10(6):e0131403. doi: 10.1371/journal.pone.0131403. eCollection 2015. PubMed 26114883 ↗
  • Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, Noh SH, Fong Y, Hyung WJ. Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg. 2017 Apr;224(4):546-555. doi: 10.1016/j.jamcollsurg.2016.12.015. Epub 2016 Dec 23. PubMed 28017807 ↗
  • Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023 May;20(5):338-349. doi: 10.1038/s41571-023-00747-0. Epub 2023 Mar 23. PubMed 36959359 ↗
  • Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998 Oct;228(4):449-61. doi: 10.1097/00000658-199810000-00002. PubMed 9790335 ↗
  • Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. doi: 10.1200/JCO.2011.36.7136. Epub 2012 May 14. PubMed 22585691 ↗
  • Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17. PubMed 22010012 ↗
  • Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453-62. doi: 10.1056/NEJMoa0707035. PubMed 18669424 ↗
  • Obermannova RL, Leong T; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025 Feb;10(2):104134. doi: 10.1016/j.esmoop.2025.104134. Epub 2025 Feb 12. PubMed 39986705 ↗
  • Movahed S, Norouzy A, Ghanbari-Motlagh A, Eslami S, Khadem-Rezaiyan M, Emadzadeh M, Nematy M, Ghayour-Mobarhan M, Varshoee Tabrizi F, Bozzetti F, Seilanian Toussi M. Nutritional Status in Patients with Esophageal Cancer Receiving Chemoradiation and Assessing the Efficacy of Usual Care for Nutritional Managements. Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2315-2323. doi: 10.31557/APJCP.2020.21.8.2315. PubMed 32856860 ↗
  • Iden CR, Mustafa SM, Ogaard N, Henriksen T, Jensen SO, Ahlborn LB, Egebjerg K, Baeksgaard L, Garbyal RS, Nedergaard MK, Achiam MP, Andersen CL, Mau-Sorensen M. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025 Jan;28(1):83-95. doi: 10.1007/s10120-024-01556-9. Epub 2024 Oct 5. PubMed 39369091 ↗
  • Liu YX, Wang XS, Wang YF, Hu XC, Yan JQ, Zhang YL, Wang W, Yang RJ, Feng YY, Gao SG, Feng XS. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. Onco Targets Ther. 2016 May 4;9:2649-54. doi: 10.2147/OTT.S102616. eCollection 2016. PubMed 27226727 ↗
  • Lin JL, Lin JX, Lin GT, Huang CM, Zheng CH, Xie JW, Wang JB, Lu J, Chen QY, Li P. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health. 2024 Jul 2;24(1):1763. doi: 10.1186/s12889-024-19104-6. PubMed 38956557 ↗
  • Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000 Sep;232(3):362-71. doi: 10.1097/00000658-200009000-00008. PubMed 10973386 ↗
  • Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. PubMed 30110194 ↗
  • Huang B, Wang Z, Xing C, Sun Z, Zhao B, Xu H. Long-term survival results and prognostic factors of early gastric cancer. Exp Ther Med. 2011 Nov;2(6):1059-1064. doi: 10.3892/etm.2011.323. Epub 2011 Jul 26. PubMed 22977620 ↗
  • Hayes M, Gillman A, Elliott JA, Donohoe CL, Reynolds JV, Regan J. The prevalence, nature and severity of oropharyngeal dysphagia in the acute post-operative phase following curative resection for esophageal cancer. Dis Esophagus. 2025 Jul 3;38(4):doaf054. doi: 10.1093/dote/doaf054. PubMed 40645642 ↗
  • Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. PubMed 29543932 ↗
  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PubMed 38572751 ↗
  • Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002 Jun 1;94(11):2862-6. doi: 10.1002/cncr.10550. PubMed 12115373 ↗
  • Anderson E, LeVee A, Kim S, Atkins K, Guan M, Placencio-Hickok V, Moshayedi N, Hendifar A, Osipov A, Gangi A, Burch M, Waters K, Cho M, Klempner S, Chao J, Kamrava M, Gong J. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Netw Open. 2021 Dec 1;4(12):e2138432. doi: 10.1001/jamanetworkopen.2021.38432. PubMed 34889947 ↗
  • Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Lohr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Guntner M, Hozaeel W, Reichart A, Jager E, Kraus T, Monig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PubMed 30982686 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 369 interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
May 4, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2034
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07565857
Lead sponsor
Natera, Inc.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2034 (estimated)
Last update
May 4, 2026

Study contacts

SIGNAL-GEC 101 Study Team
Contact
SIGNAL-GEC101@natera.com
650-489-9050
Adham Jurdi, MD
study director · Natera, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion